nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolasetron—CYP3A4—Thiotepa—urinary bladder cancer	0.112	0.36	CbGbCtD
Dolasetron—CYP2C9—Fluorouracil—urinary bladder cancer	0.0628	0.201	CbGbCtD
Dolasetron—CYP2C9—Cisplatin—urinary bladder cancer	0.0533	0.171	CbGbCtD
Dolasetron—CYP2D6—Doxorubicin—urinary bladder cancer	0.0327	0.105	CbGbCtD
Dolasetron—CYP3A4—Etoposide—urinary bladder cancer	0.0305	0.0975	CbGbCtD
Dolasetron—CYP3A4—Doxorubicin—urinary bladder cancer	0.0208	0.0665	CbGbCtD
Dolasetron—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00522	0.0747	CbGpPWpGaD
Dolasetron—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00341	0.0488	CbGpPWpGaD
Dolasetron—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.0034	0.0486	CbGpPWpGaD
Dolasetron—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00284	0.0407	CbGpPWpGaD
Dolasetron—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00241	0.0345	CbGpPWpGaD
Dolasetron—CYP2C9—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00239	0.0342	CbGpPWpGaD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00195	0.028	CbGpPWpGaD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00194	0.0278	CbGpPWpGaD
Dolasetron—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00185	0.0265	CbGpPWpGaD
Dolasetron—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00178	0.0255	CbGpPWpGaD
Dolasetron—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00158	0.0226	CbGpPWpGaD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00146	0.0209	CbGpPWpGaD
Dolasetron—HTR3A—Ion channel transport—TRPV1—urinary bladder cancer	0.00136	0.0195	CbGpPWpGaD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00128	0.0183	CbGpPWpGaD
Dolasetron—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00112	0.0161	CbGpPWpGaD
Dolasetron—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00107	0.0154	CbGpPWpGaD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000965	0.0138	CbGpPWpGaD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000937	0.0134	CbGpPWpGaD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000929	0.0133	CbGpPWpGaD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000925	0.0132	CbGpPWpGaD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000917	0.0131	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000834	0.0119	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000803	0.0115	CbGpPWpGaD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00076	0.0109	CbGpPWpGaD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000753	0.0108	CbGpPWpGaD
Dolasetron—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00075	0.0107	CbGpPWpGaD
Dolasetron—Constipation—Gemcitabine—urinary bladder cancer	0.000705	0.00114	CcSEcCtD
Dolasetron—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000705	0.00114	CcSEcCtD
Dolasetron—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000704	0.00114	CcSEcCtD
Dolasetron—Asthenia—Thiotepa—urinary bladder cancer	0.000704	0.00114	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000701	0.00113	CcSEcCtD
Dolasetron—Abdominal distension—Epirubicin—urinary bladder cancer	0.000699	0.00113	CcSEcCtD
Dolasetron—Ataxia—Doxorubicin—urinary bladder cancer	0.000699	0.00113	CcSEcCtD
Dolasetron—Dysuria—Methotrexate—urinary bladder cancer	0.000694	0.00112	CcSEcCtD
Dolasetron—Pruritus—Thiotepa—urinary bladder cancer	0.000694	0.00112	CcSEcCtD
Dolasetron—Pain—Fluorouracil—urinary bladder cancer	0.000694	0.00112	CcSEcCtD
Dolasetron—Dehydration—Doxorubicin—urinary bladder cancer	0.000691	0.00112	CcSEcCtD
Dolasetron—Paraesthesia—Cisplatin—urinary bladder cancer	0.00069	0.00112	CcSEcCtD
Dolasetron—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00069	0.00112	CcSEcCtD
Dolasetron—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000688	0.00985	CbGpPWpGaD
Dolasetron—Tachycardia—Etoposide—urinary bladder cancer	0.000687	0.00111	CcSEcCtD
Dolasetron—Dyspnoea—Cisplatin—urinary bladder cancer	0.000686	0.00111	CcSEcCtD
Dolasetron—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000681	0.0011	CcSEcCtD
Dolasetron—Pancreatitis—Epirubicin—urinary bladder cancer	0.000681	0.0011	CcSEcCtD
Dolasetron—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00068	0.0011	CcSEcCtD
Dolasetron—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000679	0.0011	CcSEcCtD
Dolasetron—Anorexia—Etoposide—urinary bladder cancer	0.000671	0.00109	CcSEcCtD
Dolasetron—Diarrhoea—Thiotepa—urinary bladder cancer	0.000671	0.00109	CcSEcCtD
Dolasetron—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000669	0.00108	CcSEcCtD
Dolasetron—Decreased appetite—Cisplatin—urinary bladder cancer	0.000668	0.00108	CcSEcCtD
Dolasetron—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000668	0.00108	CcSEcCtD
Dolasetron—Pneumonia—Methotrexate—urinary bladder cancer	0.000665	0.00108	CcSEcCtD
Dolasetron—Drowsiness—Methotrexate—urinary bladder cancer	0.000662	0.00107	CcSEcCtD
Dolasetron—Hypotension—Etoposide—urinary bladder cancer	0.000658	0.00107	CcSEcCtD
Dolasetron—Pain—Cisplatin—urinary bladder cancer	0.000658	0.00106	CcSEcCtD
Dolasetron—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000656	0.00106	CcSEcCtD
Dolasetron—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000652	0.00106	CcSEcCtD
Dolasetron—Dysuria—Epirubicin—urinary bladder cancer	0.000649	0.00105	CcSEcCtD
Dolasetron—Dizziness—Thiotepa—urinary bladder cancer	0.000648	0.00105	CcSEcCtD
Dolasetron—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000647	0.00105	CcSEcCtD
Dolasetron—Stomatitis—Methotrexate—urinary bladder cancer	0.000645	0.00104	CcSEcCtD
Dolasetron—Urticaria—Fluorouracil—urinary bladder cancer	0.000644	0.00104	CcSEcCtD
Dolasetron—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000641	0.00104	CcSEcCtD
Dolasetron—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000634	0.00103	CcSEcCtD
Dolasetron—Paraesthesia—Etoposide—urinary bladder cancer	0.000633	0.00102	CcSEcCtD
Dolasetron—Haematuria—Methotrexate—urinary bladder cancer	0.000631	0.00102	CcSEcCtD
Dolasetron—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00063	0.00102	CcSEcCtD
Dolasetron—Dyspnoea—Etoposide—urinary bladder cancer	0.000628	0.00102	CcSEcCtD
Dolasetron—Somnolence—Etoposide—urinary bladder cancer	0.000626	0.00101	CcSEcCtD
Dolasetron—Epistaxis—Methotrexate—urinary bladder cancer	0.000624	0.00101	CcSEcCtD
Dolasetron—Pneumonia—Epirubicin—urinary bladder cancer	0.000623	0.00101	CcSEcCtD
Dolasetron—Drowsiness—Epirubicin—urinary bladder cancer	0.000619	0.001	CcSEcCtD
Dolasetron—Rash—Thiotepa—urinary bladder cancer	0.000618	0.001	CcSEcCtD
Dolasetron—Dermatitis—Thiotepa—urinary bladder cancer	0.000618	0.001	CcSEcCtD
Dolasetron—Headache—Thiotepa—urinary bladder cancer	0.000614	0.000995	CcSEcCtD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000613	0.00877	CbGpPWpGaD
Dolasetron—Decreased appetite—Etoposide—urinary bladder cancer	0.000612	0.000991	CcSEcCtD
Dolasetron—Body temperature increased—Cisplatin—urinary bladder cancer	0.000608	0.000984	CcSEcCtD
Dolasetron—Fatigue—Etoposide—urinary bladder cancer	0.000607	0.000983	CcSEcCtD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000604	0.00866	CbGpPWpGaD
Dolasetron—Jaundice—Epirubicin—urinary bladder cancer	0.000603	0.000977	CcSEcCtD
Dolasetron—Stomatitis—Epirubicin—urinary bladder cancer	0.000603	0.000977	CcSEcCtD
Dolasetron—Constipation—Etoposide—urinary bladder cancer	0.000602	0.000975	CcSEcCtD
Dolasetron—Pain—Etoposide—urinary bladder cancer	0.000602	0.000975	CcSEcCtD
Dolasetron—Dysuria—Doxorubicin—urinary bladder cancer	0.000601	0.000973	CcSEcCtD
Dolasetron—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000598	0.000967	CcSEcCtD
Dolasetron—Asthenia—Gemcitabine—urinary bladder cancer	0.000592	0.000958	CcSEcCtD
Dolasetron—Haematuria—Epirubicin—urinary bladder cancer	0.00059	0.000956	CcSEcCtD
Dolasetron—Epistaxis—Epirubicin—urinary bladder cancer	0.000584	0.000945	CcSEcCtD
Dolasetron—Pruritus—Gemcitabine—urinary bladder cancer	0.000584	0.000945	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000581	0.00832	CbGpPWpGaD
Dolasetron—Feeling abnormal—Etoposide—urinary bladder cancer	0.00058	0.00094	CcSEcCtD
Dolasetron—Pneumonia—Doxorubicin—urinary bladder cancer	0.000576	0.000933	CcSEcCtD
Dolasetron—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000576	0.000933	CcSEcCtD
Dolasetron—Pruritus—Fluorouracil—urinary bladder cancer	0.000574	0.000929	CcSEcCtD
Dolasetron—Drowsiness—Doxorubicin—urinary bladder cancer	0.000573	0.000927	CcSEcCtD
Dolasetron—Visual impairment—Methotrexate—urinary bladder cancer	0.000572	0.000927	CcSEcCtD
Dolasetron—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000572	0.00819	CbGpPWpGaD
Dolasetron—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000566	0.000917	CcSEcCtD
Dolasetron—Bradycardia—Epirubicin—urinary bladder cancer	0.000566	0.000916	CcSEcCtD
Dolasetron—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000564	0.000914	CcSEcCtD
Dolasetron—Urticaria—Etoposide—urinary bladder cancer	0.00056	0.000906	CcSEcCtD
Dolasetron—Jaundice—Doxorubicin—urinary bladder cancer	0.000558	0.000904	CcSEcCtD
Dolasetron—Stomatitis—Doxorubicin—urinary bladder cancer	0.000558	0.000904	CcSEcCtD
Dolasetron—Body temperature increased—Etoposide—urinary bladder cancer	0.000557	0.000902	CcSEcCtD
Dolasetron—Abdominal pain—Etoposide—urinary bladder cancer	0.000557	0.000902	CcSEcCtD
Dolasetron—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000555	0.000898	CcSEcCtD
Dolasetron—Tinnitus—Methotrexate—urinary bladder cancer	0.000554	0.000896	CcSEcCtD
Dolasetron—Asthenia—Cisplatin—urinary bladder cancer	0.000552	0.000893	CcSEcCtD
Dolasetron—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000548	0.000886	CcSEcCtD
Dolasetron—Haematuria—Doxorubicin—urinary bladder cancer	0.000546	0.000884	CcSEcCtD
Dolasetron—Epistaxis—Doxorubicin—urinary bladder cancer	0.00054	0.000875	CcSEcCtD
Dolasetron—Dizziness—Fluorouracil—urinary bladder cancer	0.000536	0.000868	CcSEcCtD
Dolasetron—Visual impairment—Epirubicin—urinary bladder cancer	0.000536	0.000867	CcSEcCtD
Dolasetron—Chills—Methotrexate—urinary bladder cancer	0.000533	0.000863	CcSEcCtD
Dolasetron—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000527	0.00755	CbGpPWpGaD
Dolasetron—Diarrhoea—Cisplatin—urinary bladder cancer	0.000526	0.000852	CcSEcCtD
Dolasetron—Bradycardia—Doxorubicin—urinary bladder cancer	0.000524	0.000848	CcSEcCtD
Dolasetron—Rash—Gemcitabine—urinary bladder cancer	0.00052	0.000842	CcSEcCtD
Dolasetron—Dermatitis—Gemcitabine—urinary bladder cancer	0.00052	0.000841	CcSEcCtD
Dolasetron—Hypersensitivity—Etoposide—urinary bladder cancer	0.000519	0.00084	CcSEcCtD
Dolasetron—Tinnitus—Epirubicin—urinary bladder cancer	0.000518	0.000839	CcSEcCtD
Dolasetron—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000517	0.0074	CbGpPWpGaD
Dolasetron—Headache—Gemcitabine—urinary bladder cancer	0.000517	0.000837	CcSEcCtD
Dolasetron—Flushing—Epirubicin—urinary bladder cancer	0.000516	0.000835	CcSEcCtD
Dolasetron—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000512	0.00734	CbGpPWpGaD
Dolasetron—Rash—Fluorouracil—urinary bladder cancer	0.000511	0.000828	CcSEcCtD
Dolasetron—Dermatitis—Fluorouracil—urinary bladder cancer	0.000511	0.000827	CcSEcCtD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00051	0.0073	CbGpPWpGaD
Dolasetron—Headache—Fluorouracil—urinary bladder cancer	0.000508	0.000823	CcSEcCtD
Dolasetron—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000507	0.00082	CcSEcCtD
Dolasetron—Dysgeusia—Methotrexate—urinary bladder cancer	0.000506	0.00082	CcSEcCtD
Dolasetron—Asthenia—Etoposide—urinary bladder cancer	0.000505	0.000818	CcSEcCtD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000505	0.00724	CbGpPWpGaD
Dolasetron—Chills—Epirubicin—urinary bladder cancer	0.000499	0.000807	CcSEcCtD
Dolasetron—Pruritus—Etoposide—urinary bladder cancer	0.000498	0.000807	CcSEcCtD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000497	0.00711	CbGpPWpGaD
Dolasetron—Arrhythmia—Epirubicin—urinary bladder cancer	0.000497	0.000804	CcSEcCtD
Dolasetron—Visual impairment—Doxorubicin—urinary bladder cancer	0.000496	0.000802	CcSEcCtD
Dolasetron—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000495	0.00708	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.00049	0.00702	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.00049	0.00702	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000486	0.00695	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000486	0.00695	CbGpPWpGaD
Dolasetron—Rash—Cisplatin—urinary bladder cancer	0.000485	0.000785	CcSEcCtD
Dolasetron—Dermatitis—Cisplatin—urinary bladder cancer	0.000484	0.000784	CcSEcCtD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000483	0.00692	CbGpPWpGaD
Dolasetron—Diarrhoea—Etoposide—urinary bladder cancer	0.000482	0.00078	CcSEcCtD
Dolasetron—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00048	0.000777	CcSEcCtD
Dolasetron—Tinnitus—Doxorubicin—urinary bladder cancer	0.000479	0.000776	CcSEcCtD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000479	0.00686	CbGpPWpGaD
Dolasetron—Anaemia—Methotrexate—urinary bladder cancer	0.000478	0.000774	CcSEcCtD
Dolasetron—Flushing—Doxorubicin—urinary bladder cancer	0.000477	0.000773	CcSEcCtD
Dolasetron—Flatulence—Epirubicin—urinary bladder cancer	0.000477	0.000772	CcSEcCtD
Dolasetron—Dysgeusia—Epirubicin—urinary bladder cancer	0.000474	0.000767	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000473	0.00678	CbGpPWpGaD
Dolasetron—Malaise—Methotrexate—urinary bladder cancer	0.000466	0.000755	CcSEcCtD
Dolasetron—Dizziness—Etoposide—urinary bladder cancer	0.000466	0.000754	CcSEcCtD
Dolasetron—Vertigo—Methotrexate—urinary bladder cancer	0.000464	0.000752	CcSEcCtD
Dolasetron—Chills—Doxorubicin—urinary bladder cancer	0.000461	0.000747	CcSEcCtD
Dolasetron—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000459	0.000744	CcSEcCtD
Dolasetron—Cough—Methotrexate—urinary bladder cancer	0.000451	0.00073	CcSEcCtD
Dolasetron—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000449	0.000727	CcSEcCtD
Dolasetron—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000448	0.00642	CbGpPWpGaD
Dolasetron—Convulsion—Methotrexate—urinary bladder cancer	0.000448	0.000725	CcSEcCtD
Dolasetron—Anaemia—Epirubicin—urinary bladder cancer	0.000447	0.000724	CcSEcCtD
Dolasetron—Agitation—Epirubicin—urinary bladder cancer	0.000445	0.00072	CcSEcCtD
Dolasetron—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000444	0.00636	CbGpPWpGaD
Dolasetron—Rash—Etoposide—urinary bladder cancer	0.000444	0.000719	CcSEcCtD
Dolasetron—Dermatitis—Etoposide—urinary bladder cancer	0.000444	0.000718	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000443	0.00635	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000442	0.00633	CbGpPWpGaD
Dolasetron—Headache—Etoposide—urinary bladder cancer	0.000441	0.000714	CcSEcCtD
Dolasetron—Flatulence—Doxorubicin—urinary bladder cancer	0.000441	0.000714	CcSEcCtD
Dolasetron—Chest pain—Methotrexate—urinary bladder cancer	0.00044	0.000713	CcSEcCtD
Dolasetron—Myalgia—Methotrexate—urinary bladder cancer	0.00044	0.000713	CcSEcCtD
Dolasetron—Arthralgia—Methotrexate—urinary bladder cancer	0.00044	0.000713	CcSEcCtD
Dolasetron—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000438	0.00071	CcSEcCtD
Dolasetron—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000438	0.00627	CbGpPWpGaD
Dolasetron—Malaise—Epirubicin—urinary bladder cancer	0.000436	0.000706	CcSEcCtD
Dolasetron—Discomfort—Methotrexate—urinary bladder cancer	0.000435	0.000704	CcSEcCtD
Dolasetron—Vertigo—Epirubicin—urinary bladder cancer	0.000435	0.000704	CcSEcCtD
Dolasetron—Syncope—Epirubicin—urinary bladder cancer	0.000434	0.000702	CcSEcCtD
Dolasetron—Palpitations—Epirubicin—urinary bladder cancer	0.000428	0.000692	CcSEcCtD
Dolasetron—Confusional state—Methotrexate—urinary bladder cancer	0.000425	0.000689	CcSEcCtD
Dolasetron—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000425	0.000688	CcSEcCtD
Dolasetron—Cough—Epirubicin—urinary bladder cancer	0.000422	0.000683	CcSEcCtD
Dolasetron—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000422	0.000683	CcSEcCtD
Dolasetron—Convulsion—Epirubicin—urinary bladder cancer	0.000419	0.000679	CcSEcCtD
Dolasetron—Hypertension—Epirubicin—urinary bladder cancer	0.000418	0.000676	CcSEcCtD
Dolasetron—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000415	0.000672	CcSEcCtD
Dolasetron—Anaemia—Doxorubicin—urinary bladder cancer	0.000414	0.00067	CcSEcCtD
Dolasetron—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000413	0.000669	CcSEcCtD
Dolasetron—Myalgia—Epirubicin—urinary bladder cancer	0.000412	0.000667	CcSEcCtD
Dolasetron—Arthralgia—Epirubicin—urinary bladder cancer	0.000412	0.000667	CcSEcCtD
Dolasetron—Chest pain—Epirubicin—urinary bladder cancer	0.000412	0.000667	CcSEcCtD
Dolasetron—Agitation—Doxorubicin—urinary bladder cancer	0.000411	0.000666	CcSEcCtD
Dolasetron—Anxiety—Epirubicin—urinary bladder cancer	0.00041	0.000665	CcSEcCtD
Dolasetron—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000408	0.00066	CcSEcCtD
Dolasetron—Discomfort—Epirubicin—urinary bladder cancer	0.000407	0.000659	CcSEcCtD
Dolasetron—Malaise—Doxorubicin—urinary bladder cancer	0.000404	0.000654	CcSEcCtD
Dolasetron—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000403	0.00578	CbGpPWpGaD
Dolasetron—Dry mouth—Epirubicin—urinary bladder cancer	0.000403	0.000652	CcSEcCtD
Dolasetron—Vertigo—Doxorubicin—urinary bladder cancer	0.000402	0.000651	CcSEcCtD
Dolasetron—Anorexia—Methotrexate—urinary bladder cancer	0.000402	0.000651	CcSEcCtD
Dolasetron—Syncope—Doxorubicin—urinary bladder cancer	0.000401	0.00065	CcSEcCtD
Dolasetron—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.0004	0.00573	CbGpPWpGaD
Dolasetron—Confusional state—Epirubicin—urinary bladder cancer	0.000398	0.000645	CcSEcCtD
Dolasetron—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000398	0.0057	CbGpPWpGaD
Dolasetron—Palpitations—Doxorubicin—urinary bladder cancer	0.000396	0.00064	CcSEcCtD
Dolasetron—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000395	0.000639	CcSEcCtD
Dolasetron—Oedema—Epirubicin—urinary bladder cancer	0.000395	0.000639	CcSEcCtD
Dolasetron—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000394	0.00565	CbGpPWpGaD
Dolasetron—Hypotension—Methotrexate—urinary bladder cancer	0.000394	0.000638	CcSEcCtD
Dolasetron—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000393	0.000637	CcSEcCtD
Dolasetron—Cough—Doxorubicin—urinary bladder cancer	0.000391	0.000632	CcSEcCtD
Dolasetron—Shock—Epirubicin—urinary bladder cancer	0.000388	0.000629	CcSEcCtD
Dolasetron—Convulsion—Doxorubicin—urinary bladder cancer	0.000388	0.000628	CcSEcCtD
Dolasetron—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000387	0.000626	CcSEcCtD
Dolasetron—Hypertension—Doxorubicin—urinary bladder cancer	0.000386	0.000626	CcSEcCtD
Dolasetron—Tachycardia—Epirubicin—urinary bladder cancer	0.000385	0.000624	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000384	0.000622	CcSEcCtD
Dolasetron—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000382	0.000618	CcSEcCtD
Dolasetron—Chest pain—Doxorubicin—urinary bladder cancer	0.000381	0.000617	CcSEcCtD
Dolasetron—Arthralgia—Doxorubicin—urinary bladder cancer	0.000381	0.000617	CcSEcCtD
Dolasetron—Myalgia—Doxorubicin—urinary bladder cancer	0.000381	0.000617	CcSEcCtD
Dolasetron—Anxiety—Doxorubicin—urinary bladder cancer	0.00038	0.000615	CcSEcCtD
Dolasetron—Paraesthesia—Methotrexate—urinary bladder cancer	0.000379	0.000613	CcSEcCtD
Dolasetron—Discomfort—Doxorubicin—urinary bladder cancer	0.000377	0.00061	CcSEcCtD
Dolasetron—Anorexia—Epirubicin—urinary bladder cancer	0.000376	0.000609	CcSEcCtD
Dolasetron—Dyspnoea—Methotrexate—urinary bladder cancer	0.000376	0.000609	CcSEcCtD
Dolasetron—Somnolence—Methotrexate—urinary bladder cancer	0.000375	0.000607	CcSEcCtD
Dolasetron—Dry mouth—Doxorubicin—urinary bladder cancer	0.000373	0.000603	CcSEcCtD
Dolasetron—Dyspepsia—Methotrexate—urinary bladder cancer	0.000371	0.000601	CcSEcCtD
Dolasetron—Hypotension—Epirubicin—urinary bladder cancer	0.000369	0.000597	CcSEcCtD
Dolasetron—Confusional state—Doxorubicin—urinary bladder cancer	0.000368	0.000596	CcSEcCtD
Dolasetron—Decreased appetite—Methotrexate—urinary bladder cancer	0.000367	0.000594	CcSEcCtD
Dolasetron—Oedema—Doxorubicin—urinary bladder cancer	0.000365	0.000591	CcSEcCtD
Dolasetron—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000365	0.000591	CcSEcCtD
Dolasetron—Fatigue—Methotrexate—urinary bladder cancer	0.000364	0.000589	CcSEcCtD
Dolasetron—Pain—Methotrexate—urinary bladder cancer	0.000361	0.000584	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00036	0.000582	CcSEcCtD
Dolasetron—Shock—Doxorubicin—urinary bladder cancer	0.000359	0.000582	CcSEcCtD
Dolasetron—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000358	0.000579	CcSEcCtD
Dolasetron—Tachycardia—Doxorubicin—urinary bladder cancer	0.000357	0.000577	CcSEcCtD
Dolasetron—Paraesthesia—Epirubicin—urinary bladder cancer	0.000355	0.000574	CcSEcCtD
Dolasetron—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000353	0.000572	CcSEcCtD
Dolasetron—Dyspnoea—Epirubicin—urinary bladder cancer	0.000352	0.00057	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000352	0.00504	CbGpPWpGaD
Dolasetron—Somnolence—Epirubicin—urinary bladder cancer	0.000351	0.000568	CcSEcCtD
Dolasetron—Anorexia—Doxorubicin—urinary bladder cancer	0.000348	0.000564	CcSEcCtD
Dolasetron—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000348	0.000563	CcSEcCtD
Dolasetron—Dyspepsia—Epirubicin—urinary bladder cancer	0.000348	0.000563	CcSEcCtD
Dolasetron—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000345	0.000559	CcSEcCtD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000345	0.00493	CbGpPWpGaD
Dolasetron—Decreased appetite—Epirubicin—urinary bladder cancer	0.000343	0.000556	CcSEcCtD
Dolasetron—Hypotension—Doxorubicin—urinary bladder cancer	0.000341	0.000553	CcSEcCtD
Dolasetron—Fatigue—Epirubicin—urinary bladder cancer	0.00034	0.000551	CcSEcCtD
Dolasetron—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000338	0.00484	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000338	0.00484	CbGpPWpGaD
Dolasetron—Pain—Epirubicin—urinary bladder cancer	0.000338	0.000547	CcSEcCtD
Dolasetron—Constipation—Epirubicin—urinary bladder cancer	0.000338	0.000547	CcSEcCtD
Dolasetron—Urticaria—Methotrexate—urinary bladder cancer	0.000335	0.000543	CcSEcCtD
Dolasetron—Body temperature increased—Methotrexate—urinary bladder cancer	0.000334	0.00054	CcSEcCtD
Dolasetron—Abdominal pain—Methotrexate—urinary bladder cancer	0.000334	0.00054	CcSEcCtD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000333	0.00477	CbGpPWpGaD
Dolasetron—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000333	0.000539	CcSEcCtD
Dolasetron—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000328	0.000531	CcSEcCtD
Dolasetron—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000326	0.000527	CcSEcCtD
Dolasetron—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000325	0.000527	CcSEcCtD
Dolasetron—Somnolence—Doxorubicin—urinary bladder cancer	0.000325	0.000526	CcSEcCtD
Dolasetron—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000323	0.000523	CcSEcCtD
Dolasetron—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000322	0.000521	CcSEcCtD
Dolasetron—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.00032	0.00459	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.00032	0.00459	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00032	0.00458	CbGpPWpGaD
Dolasetron—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000318	0.000514	CcSEcCtD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000316	0.00452	CbGpPWpGaD
Dolasetron—Fatigue—Doxorubicin—urinary bladder cancer	0.000315	0.00051	CcSEcCtD
Dolasetron—Urticaria—Epirubicin—urinary bladder cancer	0.000314	0.000508	CcSEcCtD
Dolasetron—Pain—Doxorubicin—urinary bladder cancer	0.000312	0.000506	CcSEcCtD
Dolasetron—Constipation—Doxorubicin—urinary bladder cancer	0.000312	0.000506	CcSEcCtD
Dolasetron—Body temperature increased—Epirubicin—urinary bladder cancer	0.000312	0.000505	CcSEcCtD
Dolasetron—Abdominal pain—Epirubicin—urinary bladder cancer	0.000312	0.000505	CcSEcCtD
Dolasetron—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000311	0.000503	CcSEcCtD
Dolasetron—Asthenia—Methotrexate—urinary bladder cancer	0.000303	0.00049	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000302	0.00432	CbGpPWpGaD
Dolasetron—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000301	0.000487	CcSEcCtD
Dolasetron—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000299	0.000484	CcSEcCtD
Dolasetron—Pruritus—Methotrexate—urinary bladder cancer	0.000299	0.000483	CcSEcCtD
Dolasetron—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000293	0.0042	CbGpPWpGaD
Dolasetron—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000291	0.000471	CcSEcCtD
Dolasetron—Urticaria—Doxorubicin—urinary bladder cancer	0.00029	0.00047	CcSEcCtD
Dolasetron—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000289	0.00414	CbGpPWpGaD
Dolasetron—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000289	0.000468	CcSEcCtD
Dolasetron—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000289	0.000468	CcSEcCtD
Dolasetron—Diarrhoea—Methotrexate—urinary bladder cancer	0.000289	0.000467	CcSEcCtD
Dolasetron—Asthenia—Epirubicin—urinary bladder cancer	0.000283	0.000459	CcSEcCtD
Dolasetron—Pruritus—Epirubicin—urinary bladder cancer	0.000279	0.000452	CcSEcCtD
Dolasetron—Dizziness—Methotrexate—urinary bladder cancer	0.000279	0.000452	CcSEcCtD
Dolasetron—Diarrhoea—Epirubicin—urinary bladder cancer	0.00027	0.000437	CcSEcCtD
Dolasetron—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000269	0.000436	CcSEcCtD
Dolasetron—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000268	0.00384	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000266	0.00381	CbGpPWpGaD
Dolasetron—Rash—Methotrexate—urinary bladder cancer	0.000266	0.000431	CcSEcCtD
Dolasetron—Dermatitis—Methotrexate—urinary bladder cancer	0.000266	0.00043	CcSEcCtD
Dolasetron—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000265	0.00379	CbGpPWpGaD
Dolasetron—Headache—Methotrexate—urinary bladder cancer	0.000264	0.000428	CcSEcCtD
Dolasetron—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000264	0.00378	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000262	0.00376	CbGpPWpGaD
Dolasetron—Asthenia—Doxorubicin—urinary bladder cancer	0.000262	0.000424	CcSEcCtD
Dolasetron—Dizziness—Epirubicin—urinary bladder cancer	0.000261	0.000423	CcSEcCtD
Dolasetron—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00026	0.00373	CbGpPWpGaD
Dolasetron—Pruritus—Doxorubicin—urinary bladder cancer	0.000258	0.000418	CcSEcCtD
Dolasetron—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00025	0.000405	CcSEcCtD
Dolasetron—Rash—Epirubicin—urinary bladder cancer	0.000249	0.000403	CcSEcCtD
Dolasetron—Dermatitis—Epirubicin—urinary bladder cancer	0.000249	0.000403	CcSEcCtD
Dolasetron—Headache—Epirubicin—urinary bladder cancer	0.000247	0.0004	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000245	0.00351	CbGpPWpGaD
Dolasetron—Dizziness—Doxorubicin—urinary bladder cancer	0.000242	0.000391	CcSEcCtD
Dolasetron—Rash—Doxorubicin—urinary bladder cancer	0.00023	0.000373	CcSEcCtD
Dolasetron—Dermatitis—Doxorubicin—urinary bladder cancer	0.00023	0.000373	CcSEcCtD
Dolasetron—Headache—Doxorubicin—urinary bladder cancer	0.000229	0.000371	CcSEcCtD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000227	0.00325	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000215	0.00307	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000213	0.00305	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000208	0.00298	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000206	0.00295	CbGpPWpGaD
Dolasetron—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000199	0.00285	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000176	0.00251	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000173	0.00248	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000154	0.0022	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.00015	0.00214	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000144	0.00207	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000143	0.00205	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000142	0.00204	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000141	0.00202	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.00014	0.00201	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000136	0.00195	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000133	0.0019	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000131	0.00188	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000131	0.00187	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00013	0.00186	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	9.43e-05	0.00135	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.3e-05	0.00133	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	8.84e-05	0.00127	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	8.76e-05	0.00125	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	8.67e-05	0.00124	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.55e-05	0.00122	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	8.38e-05	0.0012	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NAT1—urinary bladder cancer	8.38e-05	0.0012	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	8.31e-05	0.00119	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NAT1—urinary bladder cancer	8.31e-05	0.00119	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.17e-05	0.00117	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	7.66e-05	0.0011	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	7.6e-05	0.00109	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	6.9e-05	0.000988	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	6.84e-05	0.000979	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.52e-05	0.000933	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	6.46e-05	0.000925	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	6.35e-05	0.000909	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	6.29e-05	0.000901	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.78e-05	0.000827	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.48e-05	0.000784	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.48e-05	0.000784	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TYMP—urinary bladder cancer	5.08e-05	0.000727	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.05e-05	0.000723	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TYMP—urinary bladder cancer	5.03e-05	0.000721	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	5.01e-05	0.000717	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.83e-05	0.000692	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.59e-05	0.000657	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.55e-05	0.000652	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.51e-05	0.000646	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.26e-05	0.00061	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.15e-05	0.000594	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.96e-05	0.000567	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.93e-05	0.000563	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.67e-05	0.000526	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.67e-05	0.000526	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.64e-05	0.000521	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.64e-05	0.000521	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.62e-05	0.000518	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.56e-05	0.00051	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.53e-05	0.000505	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.47e-05	0.000498	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.32e-05	0.000475	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3e-05	0.00043	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.96e-05	0.000424	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.93e-05	0.00042	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.85e-05	0.000407	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.59e-05	0.000371	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.48e-05	0.000355	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.47e-05	0.000353	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.45e-05	0.00035	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.4e-05	0.000344	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.4e-05	0.000344	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.37e-05	0.000339	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.33e-05	0.000333	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.29e-05	0.000328	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.27e-05	0.000326	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.27e-05	0.000325	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.27e-05	0.000325	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.25e-05	0.000322	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.25e-05	0.000322	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.17e-05	0.000311	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.15e-05	0.000308	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.13e-05	0.000305	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.11e-05	0.000303	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2e-05	0.000287	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.99e-05	0.000284	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.93e-05	0.000277	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.62e-05	0.000233	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.61e-05	0.000231	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.61e-05	0.000231	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.56e-05	0.000224	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.55e-05	0.000222	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.5e-05	0.000215	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.48e-05	0.000212	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.48e-05	0.000212	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.42e-05	0.000203	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.39e-05	0.0002	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.31e-05	0.000188	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.28e-05	0.000183	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.27e-05	0.000181	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.11e-05	0.00016	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.11e-05	0.000158	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.06e-05	0.000152	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.06e-05	0.000152	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.05e-05	0.000151	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	0.000146	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	8.36e-06	0.00012	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PTEN—urinary bladder cancer	7.29e-06	0.000104	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.95e-06	9.95e-05	CbGpPWpGaD
